A Study to Detect Liver Enzyme Dysfunction among Patients on First Line Anti-Tubercular Drugs from RNTCP during the Course of Anti-TB Treatment.

Hershkovitz I, Donoghue HD, Minnikin DE, et al. Tuberculosis origin: The Neolithic scenario. Tuberculosis (Edinb) 2015;95(Suppl 1):S122-6.              

Sakula A. Robert Koch: centenary of the discovery of the tubercle bacillus, 1882. Thorax 1982;37(4):246-51.              

Global Tuberculosis Report 2018. WHO - executive summary. 2018: p. 17.

Revised National Tuberculosis Control Programme, National Strategic Plan for Tuberculosis Elimination -2017-2025: p. 5.           

Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. European Respiratory Journal 1996;9(10):2026-30.            

Kishore PV, Palaian S, Paudel R, et al. PR-drug induced hepatitis with anti-tubercular chemotherapy: challenges and difficulties in treatment. Kathmandu University Medical Journal (KUMJ) 2007;5(2):256-60.                       

Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. American Journal of Respiratory and Critical Care Med 2002;166(7):916-9.      

Isa SE, Ebonyi AO, Shehu NY, et al. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. International Journal of Mycobacteriology 2016;5(1):21-6.                        

Sharma SK, Mohan A. Antituberculosis treatment-induced hepatotoxicity: from bench to bedside. Chap - 96. In: Gupta SB, edr, Medicine Update. Mumbai: The Association of Physicians of India 2005;15:479-84.

Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. Journal of Clinical and Experimental Hepatology 2013;3(1):37-49.   

Chang KC, Leung CC, Yew WW, et al. Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? European Respiratory Journal 2007;29(2):347-51.                   

Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006;11(6):699-707.                   

Devarbhavi H, Dierkhising R, Kremers WK. et al. Single- center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. American Journal Gastroenterology 2010;105(11):2396-404.           

Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137(12):947-54.     

Kumar R, Shalimar, Bhatia V, et al. Antituberculosis therapy induced acute liver failure: magnitude, profile, prognosis and predictors of outcome. Hepatology 2010;51(5):1665-74.               

Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008;23(2):192-202.      

Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976;84(2):181-92.          

Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969;71(6):1113-20.    

Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service Cooperative Surveillance Study. Am Rev Respir Dis 1978;117(6):991-1001.

International Union against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60(4):555-64.       

Lacroix C, Tranvouez JL, Hoang PT, et al. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency. Arzneimittelforschung 1990;40(1):76-9.  

Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996;22(3):211-4.            

Dossing M, Wilcke JT, Askgaard DS, et al. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996;77(4):335-40.  

Gulati K, Ray A, Vijayan VK. Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction. Indian J Exp Biol 2010;48(3):318-22.         

Vijayalakshmi A, Thanmayi G, Jayakumari S. A prospective study on abnormal liver function test patterns in patients receiving anti-tuberculosis therapy. Asian J Pharm Clin Res 2016;9(5):136-9.         

Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis. 2010;50(6):833-9.            

Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978;59(1):13-32.          

Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996;77(1):37-42.                      

Sharifzadeh M, Rasoulinejad M, Valipour F, et al. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment. Pharmacol Res 2005;51(4):353-8.                    

Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128(1):116-23.